Table 3.

Effect of ifosfamide (IFO), propionyl-l-carnitine (PLC), D-carnitine-mildronate (DC-MD) and their combination on serum creatine phosphokinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) in rats.

Treatment groups	CK-MB (U/L)	LDH (U/L)
Control	353.60 ± 8.06	344.47 ± 19.60
DC-MD	464.67 ± 27.43	440.40 ± 23.96
PLC	308.40 ± 19.87	348.40 ± 25.83
IFO	547.01 ± 21.40*	616.80 ± 23.20*
IFO plus DC-MD	733.80 ± 35.10*$	695.60 ± 40.01*$
IFO plus PLC	351.42 ± 21.80#	432.60 ± 23.60#

Rats were randomly divided into 6 different groups of 10 animals each: Control, D-carnitine-mildronate (DC-MD, carnitine-depleted group), PLC (carnitine supplemented group), IFO, DC-MD plus IFO and PLC plus IFO. Carnitine depletion was induced in rats by daily intraperitoneal injection of DC (250 mg/kg/day) combined with MD (200 mg/kg/day) for 10 successive days. Carnitine supplementation was induced in rats by daily intraperitoneal injection of PLC (250 mg/kg/day) for 10 successive days. Fanconi Syndrome was induced in rats by administration of IFO (50 mg/kg/day, I.P.) for 5 successive days. IFO-carnitine depleted rats were given the same doses of DC-MD for 5 days before and 5 days concomitant with IFO. IFO-carnitine supplemented rats were given the same doses of PLC for 5 days before and 5 days concomitant with IFO. At the end of the treatment protocol, CK-MB and LDH, indices of cardiotoxicity, were measured in serum. Data are presented as mean ± S.E.M. (n = 10). ^*, ^# and ^$ indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test. Data are presented as mean ± S.E.M. (n = 10). ^*, ^# and ^$ indicate significant change from control, IFO and DC-MD respectively, at p < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.